Sou Hu Cai Jing·2025-12-08 09:59Core Viewpoint - Fosun Pharma's stock price increased by 0.7% to 27.33 yuan, with a total market capitalization of 72.983 billion yuan, following the announcement of new drugs being included in the national medical insurance and commercial insurance innovation drug directories [1] Group 1: Stock Performance - As of December 8, 2025, Fosun Pharma's stock opened at 27.5 yuan, reached a high of 27.6 yuan, and a low of 27.28 yuan, with a trading volume of 3.57 billion yuan and a turnover rate of 0.62% [1] Group 2: Drug Inclusion Announcement - Fosun Pharma announced that several of its drugs have been newly included in the 2025 National Medical Insurance Directory and the Commercial Health Insurance Innovation Drug Directory, effective January 1, 2026 [1] - Newly included drugs in the national medical insurance directory include Luvofexin tablets, Vorasine citrate capsules, and Pirfenidone oral suspension, while Akaluzumab injection is included in the commercial insurance innovation drug directory [1] Group 3: Financial Impact - The sales revenue of the newly included drugs is expected to account for approximately 0.98% of the group's revenue in 2024 and about 3.04% in the first three quarters of 2025 [1] - The inclusion of these drugs is anticipated to enhance drug accessibility and market promotion, positively impacting future annual performance, although the specific effects are subject to various factors [1]